XNAS · PRQR
+2.15% · +$0.0400 · Vol 432.2K
After hours · updated 16:00:00 ET
ProQR Therapeutics N.V. Ordinary Shares

ProQR Therapeutics N.V. Ordinary Shares

$1.90
Card
Relationship Map

Follow $PRQR

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $PRQR by email

Veridion Score

BETALOW CONF · 4 of 6 factors measuredMethodology

snapshot unavailable for PRQR. Cause unavailable.

Earnings absence reason unknown · Sentiment absence reason unknown
PRQR
ProQR Therapeutics N.V. Ordinary Shares
Stale score · Mon Sep 21 · completed session · 22h old · Scheduled each trading day · Markets closed · resumes Wed 9:30 ET
Middle range

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

56/ 100
Veridion Score
Middle range · LOW confidence · 4 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Confidence: LOW · 4 of 6 factors measured · Stale score · Mon Sep 21 · completed session · 22h old · Scheduled each trading day · Markets closed · resumes Wed 9:30 ET
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is PRQR moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading PRQR catalysts
About ProQR Therapeutics N.V. Ordinary Shares
Listed since
2014
Employees
187
Country
US

ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.

Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$1.87
Day high
$1.91
Day low
$1.84
Previous close
$1.86
52W high
$3.05
-37.70% from high
52W low
$1.37
32% of range
Market cap
$262.5M
Beta
1.54
Shares out
141.1M
Volume
432.2K
0.55× rel vol
Avg volume
790.4K
VWAP
$1.88
Price history computed in-house
1W
+3.26%
1M
-18.80%
3M
+4.97%
1Y
-12.04%
YTD
-5.94%
SMA 50 $1.95 · below
SMA 200 $1.77 · above
52W position 32%

PRQR overview

Loading financial statements
Loading PRQR Form 4 filings
Public disclosures

Congress activity in PRQR

No receipt-qualified Congressional disclosure is present for PRQR in the cached public ledger.

Federal contracts

PRQR contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for PRQR in this window.
Lobbying spend

PRQR lobbying filings, year to date.

Registered lobbying filings matched to ProQR Therapeutics N.V. Ordinary Shares.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for PRQR in this window.
Loading news for PRQR
Analyst ratings
Sovereign unlock shows live analyst consensus for PRQR.
Options
Sovereign unlock shows live options positioning for PRQR.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.